Treatment of Bevacizumab and Triamcinolone in Treatment or Macular Edema Secondary to CRVO (MECROV)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified November 2007 by Asociación para Evitar la Ceguera en México.
Recruitment status was  Recruiting
Information provided by:
Asociación para Evitar la Ceguera en México Identifier:
First received: November 30, 2007
Last updated: NA
Last verified: November 2007
History: No changes posted
Treatment of macular edema secondary to central retinal vein occlusion is more effective with combined therapy of bevacizumab and triamcinolone than bevacizumab alone.

Condition Intervention Phase
Macular Edema
Central Retinal Vein Occlusion
Drug: bevacizumab and triamcinolone
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Combined Treatment of Intravitreous Bevacizumab and Triamcinolone for the Treatment or Macular Edema Secondary to Central Retinal Vein Occlusion

Resource links provided by NLM:

Further study details as provided by Asociación para Evitar la Ceguera en México:

Primary Outcome Measures:
  • Changes in Best corrected visual acuity and macular edema measured with OCT [ Time Frame: Follow up to 3 , 6 and 12 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Report treatment complications [ Time Frame: 12 month ] [ Designated as safety issue: No ]

Estimated Enrollment: 10
Study Start Date: June 2007
Estimated Study Completion Date: March 2008
Intervention Details:
    Drug: bevacizumab and triamcinolone
    three applications monthly administrated of bevacizumab 2.5mg for group 1 and bevacizumab 2.5 mg + triamcinolone 4mg first dose followed by two of bevacizumab alone for the group 2
Detailed Description:
Comparison of two groups with different treatment with registrations of outcome in BCVA and complications

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Macular edema secondary to central retinal vein occlusion
  • BCVA worse than 20/40
  • Central macular >250 mc with OCT

Exclusion Criteria:

  • Diabetic retinopathy or other retinopathy
  • Media opacity that does not allow following
  • steroid responder
  • diagnosed glaucoma or IOP > 21 mmHg
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00566761

Contact: Carmen Conzalez-Mijares, Physician 5517638245

Asociacion Para Evitar la Ceguera en Mexico Recruiting
Mexico city, Coyoacan, Mexico, 04030
Contact: Retina Department    5510841400 ext 1171   
Sponsors and Collaborators
Asociación para Evitar la Ceguera en México
Principal Investigator: Carmen Gonzalez-Mijares, Physician APEC
Study Director: Hugo Quiroz-Mercado, Retinologyst APEC
Study Chair: Juan Manuel Jimenez Sierra, Retinologyst APEC
Study Chair: MA Martinez-Castellanos, Physician APEC
Study Chair: Octavio Burgos Vejar, Physician APEC
Study Chair: Raul Velez-Montoya, Physician APEC
Study Chair: Ma de Lourdes Lopez Ramos, Physician APEC
Study Chair: Omar Honerlager, preresident APEC
  More Information

Responsible Party: Carmen Cecilia Gonzalez Mijares, Asociación para Evitar la Ceguera en Mexico IAP Identifier: NCT00566761     History of Changes
Other Study ID Numbers: MECRVO 
Study First Received: November 30, 2007
Last Updated: November 30, 2007
Health Authority: Mexico: Ethics Committee

Keywords provided by Asociación para Evitar la Ceguera en México:
Macular edema
central retinal vein occlusion

Additional relevant MeSH terms:
Macular Edema
Retinal Vein Occlusion
Cardiovascular Diseases
Embolism and Thrombosis
Eye Diseases
Macular Degeneration
Retinal Degeneration
Retinal Diseases
Signs and Symptoms
Vascular Diseases
Venous Thrombosis
Triamcinolone Acetonide
Triamcinolone diacetate
Triamcinolone hexacetonide
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Anti-Inflammatory Agents
Antineoplastic Agents
Enzyme Inhibitors
Growth Inhibitors
Growth Substances
Hormones, Hormone Substitutes, and Hormone Antagonists
Immunologic Factors
Immunosuppressive Agents processed this record on May 26, 2016